We investigated the effect of
NIP-121, a novel
ATP-sensitive K+ channel opener, on myocardial damage during
ischemia/reperfusion. The action potential and contractile force of coronary-perfused guinea pig right ventricular walls were recorded. The preparations were subjected to 30-min no-flow
ischemia with or without
NIP-121 or
glibenclamide, followed by 60-min reperfusion. In untreated tissues, decreases in action potential duration (APD) and contractile force and an increase in resting tension were observed during the no-flow period. On reperfusion, transient arrhythmias were observed and resting or contractile force returned to <50% of preischemic values.
NIP-121, at 0.3 microM, a concentration showing only a slight negative inotropic effect, caused a faster decrease in APD and contractile force but abolished the increase in resting tension (RT) during the no-flow period. On reperfusion, no
arrhythmia was observed in NIP-121-treated preparations, and contractile force recovered to approximately 80% of the preischemic value.
Glibenclamide 1 microM attenuated the decrease in APD but affected neither the decrease in contractile force nor the increase in RT during the no-flow period. On reperfusion, the incidence of
arrhythmia was increased in
glibenclamide-treated preparations, and the recovery of basal tension and contractile force was inhibited: Contractile force recovered to only approximately 15% of the preischemic value.
NIP-121 was also shown to attenuate the decrease in tissue
ATP during
ischemia and reperfusion. We demonstrated that
NIP-121 may have protective effects against myocardial injury during
ischemia and reperfusion. Activation of
ATP-sensitive K+ current may be an adaptive mechanism for cardioprotection under compromised blood flow.